LAMICTAL        SUPPORTING DATA 
Prevents depression
Does not destabilize mood
Improves quality of life
Tolerability similar to placebo
No weight gain
13 years of experience
A new approach
Introduce at any phase
Can be used in combination
Supporting data
Supported by GSK.
(c) 2004 Excerpta Medica
All rights reserved.
Disclaimer
print this page
 Concomitant lamotrigine use with lithium or valproate*

Authors: Bowden C, et al.
Title: Concomitant use of lamotrigine with lithium or valproate in bipolar I disorder.
Reference: World J Biol Psychiatry 2004;5(Suppl 1):48. 
Purpose: To evaluate the efficacy and safety of lamotrigine and lithium, and lamotrigine and valproate, in patients with bipolar disorder.
Study design: Pooled data from the preliminary open-label phase of two large maintenance trials.
Follow up: 8–16 weeks.
Patients: 492 (292 lamotrigine and lithium, 200 lamotrigine and valproate).
Treatment: Not specified.
Results: Improvement of mean CGI-S and GAS scores was observed with either combination therapy. Concomitant administration seemed to be effective. Combination therapy was well-tolerated and the most common adverse events were headache, nausea, diarrhea, infection, and rash. No cases of serious rash were reported. No significant differences in rash were observed with or without combination treatment with valproate.

*Sponsored by GSK

clinical global impressions severity
Global Assessment Scale
Global Assessment Scale


 
  
home help sitemap acronyms help sitemap home